Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical ...

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has ...

Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, ...

Poseida will carry out development work on the BCMA and CD19/CD20 CAR-Ts through to the end of the phase 1 dose-escalation stage, with the work largely funded by Roche, according to an SEC filing.

Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida's clinical and pre-clinical CAR-T therapies and manufacturing capabilities.

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

Two years after partnering with Poseida Therapeutics on off-the-shelf CAR-T therapeutics, Roche has decided it wants to take full control of the company and its technology platforms. The Swiss ...

Roche's global capabilities in late-stage development and commercialization will enable patients worldwide to benefit from the transformative potential of allo CAR-T." Poseida and its employees ...

(Alliance News) - Roche Holding AG on Wednesday said that it has completed the tender offer for all outstanding shares of Poseida Therapeutics Inc, a clinical-stage biopharmaceutical company, through ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and not ...